OptimizeRxOPRX
Recorded

OptimizeRx 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration52 minParticipants9

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, everyone, and thank you for joining OptimizeRx third quarter fiscal 2026 earnings conference call. With us today is Chief Executive Officer Stephen Silvestro. He is joined by Chief Financial and Strategy Officer Ed Stelmakh, Chief Legal and Administrative Officer Marion Odence-Ford, Chief Business Officer Andy D'Silva, and Corporate Controller Heather Favazza. At the conclusion of today's call, I will provide some important questions regarding the forward-looking statements made by management during today's call. The company will also discuss certain non-GAAP financial measures that it believes are useful in evaluating operating performance. A reconciliation of these non-GAAP measures can be found in today's earnings release, as well as in the investor relations section of the company's website. I would also like to remind everybody that today's call is being recorded and will be available for replay on the investor relations section of the company's website.

Operator

With that, I would like to turn the call over to OptimizeRx Chief Executive Officer Stephen Silvestro.

Steve SilvestroCEO

Mr. Silvestro? Thank you, operator, and good afternoon, everyone.

Steve SilvestroCEO

Thank you for joining our third quarter 2026 earnings call. We are pleased to report third quarter revenue of $21.6 million and adjusted EBITDA of $6.3 million, both of which exceeded consensus expectations. While revenue came in modestly ahead of expectations, our adjusted EBITDA performance was again particularly strong, reflecting our continued gross margin strength and the benefits of our disciplined approach to cost management. Importantly, our bottom line performance reflects the structural improvements we have made to our operating model, including the cost reduction initiative completed during the first half of the year. These actions have allowed us to operate more efficiently while continuing to invest in the technologies, products, and commercial capabilities we believe will drive long-term growth. Although the broader pharmaceutical marketing environment remains dynamic, we believe our third quarter performance demonstrates the underlying profitability and operating leverage of our business.

Steve SilvestroCEO

At the same time, we recognize that our top line performance has not yet reflected the full potential of investments we have made in our platform. Contracted revenue for 2026 continues to track approximately 20% below the comparable prior year. As a result, we have a larger amount of revenue to secure and recognize during the fourth quarter to achieve our previously issued guidance. Given this backdrop, we are updating the full year 2026 revenue guidance to a range of $87 million-$93 million, while maintaining our adjusted EBITDA guidance of $21 million-$25 million. This revision reflects expected timing of our customer spending decisions and the increased amount of business that would need to convert and be recognized before year-end to achieve our previous revenue expectations. We remain encouraged by the sustainable progress we are making across our business, including a very encouraging start to 2027.

Steve SilvestroCEO

We are seeing expanded opportunities within key accounts, indications of pent-up demand as customers ramp up the 2027 RFP season, and growing commercial opportunities associated with our programmatic distribution capabilities. We are also pleased to report that one of our previously displaced top 5 clients has returned and begun to reinvest in new solutions with OptimizeRx. As you may recall, this customer represented a meaningful portion of our revenue in 2025, but had not generated revenue during the first three quarters of 2026. We are now pleased to report that we have begun generating revenue from this customer during the fourth quarter. While spending has not yet returned to historical levels, we view this as a positive development and an encouraging indication of renewed customer engagement and interest and contribution to growth next year in 2027. In addition, we are encouraged by the progress we have made by strengthening our commercial organization.

Steve SilvestroCEO

During the third quarter, Sarah Bast joined OptimizeRx as Chief Marketing Officer, bringing more than two decades of pharmaceutical marketing experience, including significant leadership roles in point-of-care media and agency partnerships. Her appointment represents an important investment in executing our go-to-market strategy as we seek to deepen relationships with pharmaceutical manufacturers, strengthen our position with leading healthcare marketing agencies, and accelerate adoption of our expanding product portfolio. Importantly, we believe our revised outlook reflects the near-term timing and conversion of customer spending rather than a change in our long-term market opportunity. Our focus remains on converting these opportunities into revenue while maintaining the financial discipline and operational efficiency that have driven our strong profitability and performance. Ed will provide additional details on our financial performance and outlook shortly.

Steve SilvestroCEO

Turning to the broader market, pharmaceutical manufacturers continue navigating an environment characterized by evolving spending priorities, budget scrutiny, and a heightened focus on measurable returns on marketing investment. While these dynamics have contributed to delays in certain customer decisions and the timing of campaign execution, we continue to hear encouraging feedback regarding the underlying demand for our solutions. It is important to state here that OptimizeRx is uniquely positioned as the only tech company in this space with a proven AI-enabled operating system that is rapidly scaling information across a proprietary network of EHR systems. Those interactions are underpinned by OptimizeRx's growing proprietary data, which enables our technology to find patients in need of therapy and the doctors who treat them.

Steve SilvestroCEO

In our conversations with our pharma and agency customers, we are seeing continued interest in solutions that improve targeting precision, deliver measurable outcomes, and reach healthcare providers and patients at the moments when engagement is most relevant. Our focus remains on translating that interest into signed agreements, active campaigns, and recognized revenue. We believe there is pent-up demand within our customer base as pharmaceutical manufacturers evaluate how and when to deploy their remaining marketing budgets. Although the timing of that spending remains difficult to predict, the underlying customer needs align closely with the capabilities we have been building across our platform. We believe the combination of stronger commercial leadership and broader distribution capabilities through our programmatic initiatives will improve our ability to capture demand as we look for customer spending to normalize in 2027.

Steve SilvestroCEO

Rather than relying solely on historical patient characteristics or static audience definitions, our technology is designed to anticipate future treatment eligibility and help pharmaceutical manufacturers engage the appropriate audiences during critical windows in the patient journey. We believe this approach represents an important advancement in how life science organizations identify and engage potential treatment candidates. We believe these proprietary and patented capabilities will become increasingly valuable as pharmaceutical manufacturers seek more sophisticated, measurable, and AI-enabled approaches to commercial engagement. We continue to make meaningful progress advancing our programmatic strategy with what we believe represents one of the most significant long-term growth opportunities for OptimizeRx. Since opening our proprietary EHR network to programmatic buying earlier this year, we have established relationships with three leading demand-side platforms: DeepIntent, The Trade Desk, and most recently, PulsePoint.

Steve SilvestroCEO

Together, these integrations are expanding access to our authenticated point-of-care inventory through the platforms pharmaceutical manufacturers and agencies already use to plan and execute their campaigns. in September, we announced an integration with The Trade Desk through its OpenPath solution, providing advertisers with access to over 800,000 verified healthcare professionals across more than 400 EHR and e-prescribing systems through OptimizeRx's point-of-care network. More recently, we announced a partnership with PulsePoint, further expanding our programmatic distribution footprint. Through this integration, OptimizeRx will contribute approximately 250,000 incremental NPIs to PulsePoint's network. We expect our inventory to become available to PulsePoint advertisers throughout November. Importantly, these partnerships represent more than just additional distribution channels. They are an important step toward integrating point-of-care advertising into the broader omnichannel strategies of pharmaceutical marketers. Historically, EHR advertising has largely been purchased through direct relationships or specialized channels, often separately from the other digital investments.

Steve SilvestroCEO

Our programmatic strategy is designed to eliminate those barriers, making it easier for customers to incorporate authenticated clinical inventory into their existing media plans. By expanding access through multiple leading DSPs, we are creating new opportunities to reach advertisers, increase utilization of our proprietary network, and capture a greater share of pharmaceutical marketing budgets. While these initiatives remain in the early stages of commercialization, we believe they represent an important evolution in our business model. Rather than relying exclusively on traditional direct sales, we are building a more scalable distribution infrastructure that allows demand to flow into our network through multiple channels. We believe this strategy, combined with our differentiated AI-enabled audience intelligence and authenticated clinical inventory, positions OptimizeRx to benefit from the continued shift toward programmatic healthcare advertising and creates additional opportunities for sustainable long-term revenue growth. We also continued expanding our AI-enabled product portfolio.

Steve SilvestroCEO

in September, we announced an enhancement to our Natural Language Audience Builder, or NLAB, extending its capabilities beyond healthcare provider audiences to include privacy-safe direct-to-consumer audiences. By incorporating our micro-neighborhood targeting capabilities, NLAB now allows pharmaceutical marketers and agencies to develop coordinated HCP and consumer audiences through a unified natural language workflow. This represents an important advancement in our strategy to simplify omnichannel healthcare marketing. Rather than developing HCP and DTC campaigns through disconnected planning processes, marketers can use a common approach to identify and activate relevant audiences across both channels. We believe this improves planning efficiency, strengthens audience coordination, and creates opportunities for more effective and efficient engagement through the patient treatment journey. Together with DAAP, our programmatic integrations, and our recently introduced CopayQ solution, these capabilities are expanding the ways pharmaceutical manufacturers can engage healthcare professionals and patients through our platform.

Steve SilvestroCEO

Collectively, these initiatives reflect our evolution from a traditional point-of-care marketing business toward a broader technology-enabled platform, supporting audience intelligence, media planning, programmatic activation, and clinical workflow engagement. Over time, we believe this evolution can create additional recurring revenue opportunities, improve customer retention, and strengthen the scalability of our financial model. As we look ahead, I believe OptimizeRx is differentiated by three fundamental competitive advantages. First, we've built a proven and increasingly scalable AI-enabled platform. AI has been foundational to our technology strategy for years, and solutions such as DAAP and NLAB demonstrate our ability to translate that investment into differentiated commercial capabilities. Importantly, we believe our platform can support additional customers and use cases without a proportional increase in our cost structure. Second, our proprietary data and solutions provide meaningful differentiation in an increasingly AI-driven world.

Steve SilvestroCEO

While general-purpose AI can automate many marketing functions, we believe our combination of proprietary healthcare data, predictive intelligence, and authenticated clinical workflow access is difficult to replicate or disintermediate. Third, we've established a proprietary network with substantial reach and meaningful barriers to entry. Our integrations across more than 450 EHR and e-prescribe systems provide access to over 1.1 million verified healthcare professionals. These relationships and technical integrations have taken years to develop and form a durable competitive advantage. Together, these fundamental competitive advantages position OptimizeRx to benefit from the continued evolution of healthcare marketing toward AI-enabled planning, programmatic activation, and measurable engagement. As we move toward the end of 2026 and begin preparing for 2027, our priorities remain clear. First, we're focused on improving top-line execution and converting the commercial opportunities currently within our pipeline.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day